BIO101
/ Boostimmune
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 04, 2024
Neutralizing extracellular TCTP overcomes MDSC-mediated immunosuppression and enhances cancer immunity
(SITC 2024)
- "This suggests significant clinical benefits for patients with immune-suppressive tumors characterized by high TCTP release. BIO101 shows promise as a novel therapeutic antibody, offering potential clinical benefits for patients with TCTP-high tumors."
IO biomarker • Myeloid-derived suppressor cells • Oncology • CD4 • CD8 • TLR2
1 to 1
Of
1
Go to page
1